CJ
FATE icon

Caitlin John’s Fate Therapeutics FATE Stock Holding History

Caitlin John’s Portfolio FATE Stock Details FATE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$48 Hold
40
– – ﹤0.01% 926
2025
Q4 		$39 Hold
40
– – ﹤0.01% 918
2025
Q3 		$50 Buy
+40
New +$43 ﹤0.01% 871
2025
Q1 		– Sell
-92
Closed -$152 – 332
2024
Q4 		$152 Hold
92
– – ﹤0.01% 824
2024
Q3 		$200 Hold
92
– – ﹤0.01% 805
2024
Q2 		$302 Buy
+92
New +$403 ﹤0.01% 796

Other funds holding FATE

RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
JJ
Johnson & Johnson New Brunswick, New Jersey $652M AUM 198.07% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Caitlin John's FATE Position: Q1 2026 in Review

Caitlin John held its Fate Therapeutics (FATE) position steady in Q1 2026 at 40 shares worth $48. The position accounts for ﹤0.01% of the portfolio, ranked #926.

Caitlin John first reported a position in FATE in Q2 2024 and has held it in 6 quarters since. The position peaked at $302 in Q2 2024. 157 funds tracked by Wall St. Rank hold FATE as of Q1 2026.

  • Caitlin John held 40 shares of Fate Therapeutics worth $48 as of Q1 2026.
  • Caitlin John left its Fate Therapeutics share count unchanged in Q1 2026.
  • Fate Therapeutics made up ﹤0.01% of Caitlin John's portfolio in Q1 2026, its #926 holding.
  • Caitlin John first reported a position in Fate Therapeutics in Q2 2024 and has held it in 6 quarters since.
  • Caitlin John's Fate Therapeutics position peaked at $302 in Q2 2024.
  • 157 funds tracked by Wall St. Rank held Fate Therapeutics as of Q1 2026.

Based on Caitlin John's 13F filing for Q1 2026, filed 13 May 2026.